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Cholera is an acute, secretory diarrhoea caused by infection with Vibrio cholerae of the O1 or O139 serogroup. It is 
endemic in more than 50 countries and also causes large epidemics. Since 1817, seven cholera pandemics have 
spread from Asia to much of the world. The seventh pandemic began in 1961 and aﬀ ects 3–5 million people each year, 
killing 120 000. Although mild cholera can be indistinguishable from other diarrhoeal illnesses, the presentation of 
severe cholera is distinct, with pronounced diarrhoeal purging. Management of patients with cholera involves 
aggressive ﬂ uid replacement; eﬀ ective therapy can decrease mortality from more than 50% to less than 0·2%. 
Antibiotic treatment decreases volume and duration of diarrhoea by 50% and is recommended for patients with 
moderate to severe dehydration. Prevention of cholera depends on access to safe water and sanitation. Two oral 
cholera vaccines are available and the most eﬀ ective use of these in integrated prevention programmes is being 
actively assessed.
Introduction and history
Cholera is an acute secretory diarrhoea caused by 
the Gram-negative bacterium Vibrio cholerae.1–4 Cholera 
epidemics have been increasing in intensity, duration, 
and frequency, showing the need for more eﬀ ective 
approaches to prevention and control.
Descriptions of a disease thought to be cholera are 
found in Sanskrit back to the 5th century BC, and the 
disease has existed on the Indian subcontinent for 
centuries. In 1817, cholera spread beyond the Indian 
subcontinent, and six worldwide cholera pandemics 
occurred between 1817 and 1923. Between 1849 and 1854, 
London physician John Snow proposed that cholera 
was a communicable disease and that stool contained 
infectious material. He suggested that this infectious 
material could contaminate drinking water supplies, 
resulting in transmission of cholera. Filippo Pacini, 
working independently in Italy in 1854, ﬁ rst observed 
comma-shaped forms under a microscope in cholera 
stools. In 1884, Robert Koch ﬁ rst isolated V cholerae in 
pure culture in work that began in Egypt and continued 
in Calcutta (Kolkata), India.
The continuing seventh cholera pandemic began in 
Indonesia in 1961 and spread through Asia to Africa, 
Europe, and Latin America. This pandemic is caused by a 
new biotype of V cholerae ﬁ rst isolated in 1905 in El Tor, 
Egypt.3 Although cholera is vastly under-reported, WHO 
estimates that 3–5 million cases occur per year,5 pre-
dominantly in Asia and Africa, with periodic major 
epidemics including that in Haiti in 2010.6 Diarrhoeal 
diseases including cholera are the second leading cause 
of mortality worldwide among children younger than 
5 years, and are one of the main causes of morbidity.7 
Cholera is also a major cause of severe dehydrating 
diarrhoea in adults.
Causative agent
V cholerae is a member of the Vibrionaceae family of 
curved, Gram-negative rods that are found in coastal 
waters and estuaries.1,3 These organisms grow best in the 
presence of salt, although V cholerae can grow in water of 
low salinity when it is warm and contains suﬃ  cient 
organic nutrients.8 V cholerae is often associated with 
zooplankton and shellﬁ sh in water,8 and it can use chitin 
as a carbon and nitrogen source.9 Chitin induces natural 
competence in V cholerae, suggesting that lateral gene 
transfer occurs in water, especially during zooplankton 
blooms.10 In water, V cholerae enter a viable but non-
culturable form,11 also called active but non-culturable or 
conditionally viable environmental cells.4,12
V cholerae is classiﬁ ed into more than 200 serogroups 
based on the O antigen of the lipopolysaccharide;1 of 
these, only O1 and O139 serogroups cause epidemic 
cholera. V cholerae O1 is further classiﬁ ed into two 
biotypes, classical and El Tor.3 Two major serotypes exist, 
Ogawa and Inaba, which vary in prevalence with time.13 
In 1992, V cholerae O139 was ﬁ rst recognised in south 
Asia as a cause of epidemic cholera.14,15 This organism is 
derived from V cholerae O1 El Tor by lateral transfer of a 
genomic island substituting the O139 for the O1 antigen, 
but is otherwise almost identical to V cholerae O1 El Tor.16,17 
Although classical V cholerae O1 caused the ﬁ fth and 
sixth pandemics (and presumably the earlier pandemics), 
the seventh pandemic is attributed to the El Tor biotype, 
which has now replaced the classical biotype.
Although early isolates of V cholerae O1 were susceptible 
to most antibiotics, V cholerae O139, and some isolates of 
V cholerae O1 El Tor, have acquired an SXT element that 
mediates resistance to co-trimoxazole and streptomycin;18 
this element is found in almost all strains isolated during 
the past decade.19 In the past few years, strains of V cholerae 
O1 resistant to tetracycline, erythromycin, or ciproﬂ oxacin, 
or combin ations thereof, have been recovered in Asia;19,20 
some of these strains have acquired additional resistance 
genes in the SXT element. These multiresistant strains 
have not yet been recognised in other locations.
Search strategy and selection criteria
We searched Medline and Cochrane Library databases 
with the terms “cholera” or “Vibrio cholerae”, and 
“randomised controlled trials” from Jan 1, 1966 to 
Sept 30, 2011, in all languages. 
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Pathogenesis and pathophysiology
After ingestion of V cholerae, most of the bacteria are 
killed by gastric acid. Surviving organisms colonise the 
small intestine and elaborate cholera toxin, the major 
virulence factor for pathogenic strains.3 Cholera toxin is a 
protein exotoxin that consists of one A subunit associated 
with ﬁ ve B subunits.21 The B subunit pentamer binds to 
the ganglioside GM1 on eukaryotic cells, and the 
A subunit is translocated intracellularly, where it acts 
enzymatically to activate adenylate cyclase and raise 
intracellular cyclic AMP; this leads to chloride secretion 
through the apical chloride channel and secretory 
diarrhoea.22–24 The second major virulence factor of 
pathogenic strains of V cholerae is the toxin-coregulated 
pilus, a colonisation factor whose expression is regulated 
in parallel to cholera toxin.25,26
The genes for cholera toxin are encoded within 
the genome of a ﬁ lamentous bacteriophage, CTXφ.27 
Classical and El Tor strains have diﬀ erent versions of this 
bacteriophage, which can insert at one or two attachment 
sites in the genome depending on the biotype. The 
bacterial cell surface receptor for CTXφ is the toxin-
coregulated pilus,27 which is itself encoded within a 
genomic island—vibrio pathogenicity island (VPI-1).28,29 
Evolution of virulence in V cholerae involves sequential 
acquisition of VPI-1 followed by CTXφ.
All seventh pandemic strains of V cholerae O1 El Tor 
contain VPI-1, and a second vibrio pathogenicity island 
VPI-2. Two genomic islands are speciﬁ c to the seventh 
pandemic strains, vibrio seventh pandemic islands 1 
and 2.30 Recent seventh pandemic strains have been 
described that have the classical CTXφ instead of the 
El Tor CTXφ, or a variant of the El Tor CTXφ encoding 
the B subunit of cholera toxin that occurs in classical 
V cholerae O1 strains.31 These variant El Tor strains have 
largely replaced the earlier El Tor strains and might be 
associated with more severe diarrhoea.
Epidemiology
Cholera occurs in both endemic and epidemic patterns. 
It is endemic in many areas of Asia and Africa. In Asia, 
cholera occurs seasonally before and after the monsoon 
rains,3 the incidence is highest in children, and the 
disease can occur in neonates.32,33 Cholera epidemics 
arise in a long cycle superimposed on existing endemic 
disease. This pattern relates to declining levels of 
population-level immunity from a previous outbreak, 
overlaid on cycles of climate vari ability.34 In the past 
decade, devastating epidemics of cholera have occurred 
in Angola, Ethiopia, Zimbabwe, Pakistan, Somalia, 
Sudan, Vietnam, and Haiti.35 Among immuno logically 
naive populations, cholera aﬀ ects all age groups, and 
epidemics can be associated with high case-fatality 
rates.35 This pattern was recorded in Haiti, where cholera 
had been notably absent before 2010. Population density, 
poor sanitation and health infra structure, and logistical 
obstacles to appropriate case management also 
contribute to a high case-fatality rate in epidemic 
settings.
Environmental factors are important in the epidemi-
ology of cholera. Changes in surface water temperature 
and terrestrial nutrient discharge lead to a proliferation 
of phytoplankton and zooplankton and a consequent 
increase in V cholerae.8,36,37 Cholera rates also increase 
substantially during ﬂ oods compared with non-ﬂ ood 
periods.38 Natural disasters that disrupt public health 
facilities, such as cyclones and earthquakes, also contri-
bute to cholera epidemics.
The infectious dose of V cholerae O1 has been estimated 
to be 10⁵–10⁸ in experimental human infection, but could 
be as low as 10³ in the presence of achlorhydria.39 The 
incubation period ranges between 12 h and 5 days.1,40
Molecular epidemiology
The genome of a V cholerae O1 El Tor strain was 
sequenced in 2000;41 as with all vibrios, this organism 
has a large circular chromosome and a small circular 
chromosome.42 All Vibrionaceae have a super-integron 
in the small chromosome that acts as a gene capture 
system.43,44 A comparison of genomic sequences of 
patient and environmental strains isolated for nearly 
100 years showed 12 distinct lineages of V cholerae O1; 
the classical and El Tor O1 biotypes were one lineage in 
this phylogeny.31 All strains of V cholerae O1 El Tor 
shared a highly conserved core genome, with variations 
attributable mainly to laterally transferred genetic ele-
ments and single nucleotide variation.
An analysis suggested that the seventh pandemic 
strains originated from a single source in the Bay of 
Bengal that has spread to distant locations in three 
independent but overlapping waves.45 The ﬁ rst wave, 
which spread from Asia into Africa and South America, 
lacked the SXT element. The second wave acquired the 
SXT element and replaced the isolate in the ﬁ rst wave; 
the third wave also contains the SXT element. Isolates in 
the Haiti outbreak are closely related to south Asian 
strains in the third pandemic wave.46
Transmission
Patients infected with V cholerae O1 or O139 who have 
no symptoms generally shed the organism for only a 
few days; however, patients who are symptomatic shed 
the organism for between 2 days and 2 weeks, and 
rarely longer.4,40 Transmission of cholera within house-
holds has been documented.40 V cholerae are present in 
human stool both as individual planktonic cells and in 
bioﬁ lm-like aggregates.47,48 In environmental water, 
organisms convert to conditionally viable environmental 
cells12 within 24 h.49 These organisms are infectious on 
reintroduction into people, although the infectious 
dose in this form is not known. Filtration of water 
through sari cloth reduces cholera transmission by 
nearly 50%, consistent with removal of organisms 
attached to zooplankton.50
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The peak of a cholera epidemic is often preceded by 
increasing prevalence of the pathogenic strain in the 
environment.12 Bacteriophages that are lytic for 
V cholerae O1 or O139 are also found in the stools of 
patients and in environmental water.12,51 Bacteriophage 
den sity increases as an outbreak proceeds, and these 
bacteriophages could modulate the severity and dur-
ation of an outbreak.12,51,52
As V cholerae O1 leave a person, the organisms have a 
phenotype referred to as hyperinfectivity—that is, the 
infectious dose is 10–100 times lower than for non-
human-shed organisms.53 Hyperinfectivity of recently 
shed organisms persists in water for 5–24 h, suggesting 
that organisms transmitted from person to person might 
be more infectious than those that have acclima tised to 
the environment. When hyperinfectivity is incorporated 
into a mathematical model of a cholera outbreak, the 
character istically explosive nature of such an outbreak is 
better reproduced than if hyperinfectivity is not inclu-
ded.54 Other key components of cholera trans mission 
models4,52,55,56 include the concentration of V cholerae O1 or 
O139 in stool, the diﬀ erence of infectivity between 
planktonic cells and stool aggre gates, the rapidity of 
spread of the organism from person to person, the 
A
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Figure: Presentation and management of cholera
(A) Rice water stool in a patient with cholera. (B) Cholera cot used in management of patients with cholera to monitor continuing volume losses in stool. (C) Patient 
with cholera before rehydration. (D) Patient with cholera 8 h after starting rehydration therapy. (A, C, and D) reproduced from Chowdhury and colleagues,78 by 
permission of PLoS.
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presence of lytic bacteriophage in stool and water, and the 
concentration in water of the condition ally viable environ-
mental cells for environment-to-person transmission.
Host susceptibility
Concomitant infection with enteropathogenic bacteria 
or parasites exerts an immunomodulatory eﬀ ect on 
V cholerae-speciﬁ c immunity,57,58 and several host factors 
contribute to susceptibility to cholera. In particular, 
retinol deﬁ ciency is associated with an increased risk of 
V cholerae infection and with a raised risk of symptomatic 
disease.59,60 Blood group O has been associated with 
severe cholera in diﬀ erent populations.61–63 The preva-
lence of blood group O is lower in south Asia than in 
other regions, perhaps related to evolutionary pressure 
from cholera.64 Results of a family-based study from 
Bangladesh59 showed that ﬁ rst-degree relatives of a 
patient with cholera had greater odds of being infected 
than did less closely related contacts in the same 
household independent of blood group, suggesting that 
additional genetic factors have a role in susceptibility. 
A variant in the promoter region of BPIFB1 (also known 
as LPLUNC1), a component of the innate immune 
system, was associated with cholera in a candidate gene 
study.65,66 Additional studies of host genetic factors 
related to cholera could provide further insights into 
the interaction between V cholerae and the host.
Diagnosis
According to WHO,67 a case of cholera should be 
suspected when a patient aged 5 years or older develops 
severe dehydration or dies from acute watery diarrhoea, 
even in an area where cholera is not known to be present, 
or when a patient aged 2 years or more develops acute 
watery diarrhoea in an area known to have cholera. 
Where microbiology facilities are available, V cholerae 
infection can be conﬁ rmed by isolation of the organism 
from stool on selective media, followed by biochemical 
tests, and serogrouping and serotyping with speciﬁ c 
antibodies.68 Enrichment of stool in alkaline peptone 
water can increase the sensitivity of culture.69 Cholera 
can be rapidly diagnosed by examining fresh human 
stool under ×400 darkﬁ eld microscopy for vibrio-shaped 
cells with darting motility that is abrogated with speciﬁ c 
antibody;70 about half of culture-positive stools are 
positive on darkﬁ eld microscopy.47
Immunoassays that detect cholera toxin71,72 or V cholerae 
O1 and O139 lipopolysaccharide73–75 directly in stool 
have also been developed. Such assays can be used in 
settings with limited laboratory capacity and enable early 
detection of cases during an outbreak. One such 
commercially available dipstick for both O1 and O139-
associated cholera has a 97% sensitivity and 71–76% 
speciﬁ city compared with PCR under ﬁ eld conditions.76 
Dipstick assays seem to be more sensitive for detection 
of V cholerae in patients previously treated with anti-
biotics than is culture.
Clinical signs and symptoms
Few diseases have a clinical presentation as striking as 
that of cholera. Massive watery diarrhoea, up to 1 L per 
hour, can lead to hypotensive shock and death within 
hours of the ﬁ rst symptom (so-called cholera gravis). 
Death rates in untreated patients with severe cholera can 
exceed 70%.77 Although the stools of patients with cholera 
can contain faecal matter or bile in the early phases, the 
characteristic rice-water stool of cholera develops with 
continued purging (ﬁ gure78); this term refers to the 
similarity of the stool to water in which rice has been 
washed. Vomiting is a common feature, particularly early 
in illness. The diarrhoea of cholera is typically painless 
and not accompanied by tenesmus; some patients have 
abdominal discomfort or cramping due to ﬂ uid 
distension of the bowel. Fever is rare and should raise 
suspicion for secondary infection.
Dehydration and electrolyte abnormalities are the most 
important complications of cholera. Patients can be 
lethargic, and might have sunken eyes (ﬁ gure), dry 
mouth, cold clammy skin, decreased skin turgor, or 
wrinkled hands and feet. Kussmaul breathing can occur 
because of acidosis from stool bicarbonate losses and 
lactic acidosis associated with poor perfusion.79 The 
Sodium 
(mmol/L)
Potassium 
(mmol/L)
Chloride 
(mmol/L)
Bicarbonate 
(mmol/L)
Carbohydrate*
Electrolyte losses in stools*
Cholera stool, adult 130 20 100 45 None
Cholera stool, child 100 30 90 30 None
Non-cholera stool, child 50 35 25 20 None
Intravenous therapy†
Lactated Ringer’s solution 130 4 109 28 None 
(278 mmol/L if 
D5LR available)
Normal saline 154 0 154 0 None
Cholera saline (Dhaka solution) 133 13 98 48 140 mmol/L
Oral rehydration therapy‡
ORS (WHO 2002)§ 75 20 65 10 (citrate) 75 g (glucose)
Rice based ORS 75 20 65 10 (citrate) 27 g rice syrup 
solids
Homemade ORS95 (half teaspoon of 
salt plus six teaspoons of sugar in 
1 L of safe water)
About 75 0 About 75 0 About 75 g
A useful resource is the Cholera Outbreak Training and Shigellosis Program that provides free online information about 
the management of patients with cholera, based on WHO standards. D5LR=dextrose 5% lactated Ringer’s solution. 
ORS=oral rehydration solution. *Compositions are estimates of the mean electrolyte composition of stools and are 
provided to show the substantial diﬀ erence in the pathophysiology of paediatric and adult cholera and non-cholera 
childhood gastroenteritis. The mean maximal rate of purging in severe cholera exceeds 10 mL/kg per h. Sodium losses 
in cholera stools exceed those recorded for other causes of diarrhoeal illness. †Lactated Ringer’s solution is usually 
readily available and preferred to normal saline because it contains potassium and bicarbonate. The optimum infusion 
for cholera, such as Dhaka solution, contains more potassium and bicarbonate than lactated Ringer’s solution, and also 
contains dextrose to address complications of severe cholera including hypokalaemia, hypoglycaemia, and metabolic 
acidosis. ‡WHO ORS has glucose as a carbohydrate source. In randomised trials, rice-based ORS formulations reduced 
the duration of diarrhoea and stool losses in severe cholera.93 §In 2002, WHO replaced its previous formulation of ORS 
with the present lower osmolarity formulation. Subclinical hyponatraemia is common among patients with cholera 
with the present WHO formulation of ORS,96,97 but the rates of symptomatic hyponatraemia in patients with cholera do 
not seem to be signiﬁ cantly increased.98 
Table 1: Comparison of the composition of cholera stools and acceptable therapeutic ﬂ uids for cholera67,94
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peripheral pulse is rapid and thready, and can become 
diﬃ  cult to palpate as blood pressure drops; urine output 
decreases with time.80,81 Muscle cramping and weakness 
due to electrolyte losses and ion shifts (particularly 
potassium and calcium) are common. In children, deple-
tion of glycogen stores and inadequate gluconeogenesis 
can lead to severe hypoglycaemia, shown by altered 
consciousness, seizures, or even coma.82,83 Cholera sicca 
is an unusual form of the disease in which ﬂ uid 
accumulates in the intestinal lumen, and circulatory 
collapse and even death can occur before the passage of 
the ﬁ rst loose stool.84
The presentation of cholera diﬀ ers between endemic 
and epidemic settings. In endemic settings, rates of 
asymptomatic V cholerae infection range from 40% to 
80%,4 and cholera can present as mild diarrhoea 
indistinguishable from infection with other entero-
pathogens. The most severe cases of cholera in endemic 
settings are concentrated among young children and 
previously unexposed individuals. In the epidemic 
setting, severe disease occurs in adults as frequently as in 
children and is associated with high case-fatality rates.85 
Laboratory tests are not required to care for most patients 
with cholera although they can be useful in patients with 
ileus, confusion, coma, or seizures, or in those with no 
urine output in response to ﬂ uid replacement. Laboratory 
abnormalities include changes in serum electrolytes 
(hypokalaemia, hypo natraemia, hypocalcaemia), renal 
dysfunction, the eﬀ ects of haemoconcentration, and in a 
few children, hypo glycaemia. The clinical features of 
cholera due to V cholerae O1 and O139 are much the 
same.86,87 Compli cations from severe hypotension can 
include stroke (especially in elderly patients) and renal 
compromise, and vomiting can lead to aspiration 
pneumonia,88 but cholera itself is an acute infection with 
no chronic symptoms.
Management
Rehydration is the cornerstone of management of 
patients with cholera. Early attempts at oral rehydra-
tion met with little success because the physiological 
require ments for sodium-glucose cotransport were not 
recog nised. The introduction of oral rehydration solu-
tion in the late 1960s, with equimolar concentra tions of 
sodium and glucose to maximise sodium uptake in 
the small intestine, and careful replacement of pre-
ceding and continuing ﬂ uid losses, ushered in present 
cholera treatment.84,89
With the present standard of care, the mortality of 
severe cholera can be reduced to less than 0·2%, even 
in resource-limited settings.3 However, obstacles exist 
to administration of best possible rehydration, and 
mortality rates can still exceed 10% early in cholera 
epidemics before appropriate resources are available.90,91 
In the epidemic in Haiti, the median time between 
onset of symptoms and death within the community 
was 12 h.92 Decentralised treatment centres (such as 
oral rehydration points) improve access to therapy, 
reduce time to initial rehydration, and are crucial in 
manage ment of outbreaks.
The approach to rehydration during severe cholera 
diﬀ ers substantially from the approach to patients with 
gastroenteritis in developed countries because: patients 
with severe cholera present with a greater degree of 
initial dehydration, these patients have more rapid 
continuing losses once they come to medical attention, 
and they have proportionally greater electrolyte losses 
than in non-cholera gastroenteritis (table 193–98).
For these reasons, the most common error in caring 
for patients with cholera is to underestimate the speed 
and volume of ﬂ uids required. Patients with severe 
cholera typically require an average of 200 mL/kg of 
isotonic oral or intravenous ﬂ uids in the ﬁ rst 24 h of 
therapy, and might require more than 350 mL/kg.67,99 
Estimation and replacement of ongoing losses, even 
during correction for the initial ﬂ uid deﬁ cit, is crucial. 
The rate of continuing ﬂ uid loss might exceed 20 mL/kg 
per h; cholera cots are inexpensive and useful for 
estimation of continuing volume losses (ﬁ gure). In the 
absence of cholera cots, continuing losses can be 
estimated as 10–20 mL/kg of bodyweight for each 
diarrhoeal stool or episode of vomiting.
In severe cholera, the initial ﬂ uid deﬁ cit should be 
replaced within 3–4 h of presentation. The route of 
administration of ﬂ uids depends on the severity of 
dehydration (table 267). Patients with severe (≥10%) 
No dehydration (<5%) Some dehydraton (5–10%) Severe dehydration 
(>10%)
Clinical assessment for degree of dehydration
General appearance Well, alert Restless, irritable Lethargic or unconscious
Eyes Normal Sunken Sunken
Thirst Drinks normally Thirsty, drinks eagerly Drinks poorly or unable 
to drink
Skin turgor Instantaneous recoil Non-instantaneous recoil Very slow recoil (>2 s)
Pulse Normal Rapid, low volume Weak or absent
Approach to rehydration*
Requirement for ﬂ uid 
replacement
Ongoing losses only 75 mL/kg in addition to 
ongoing losses
>100 mL/kg in addition 
to ongoing losses
Preferred route of 
administration
Oral† Oral or intravenous Intravenous 
Timing Usually guided by thirst Replace ﬂ uids over 3–4 h As rapidly as possible 
until circulation is 
restored, complete the 
remainder of ﬂ uids 
within 3 h
Monitoring Observe until ongoing 
losses can deﬁ nitely be 
adequately replaced by ORS
Observe every 1–2 h until 
all signs of dehydration 
resolve and patient urinates
Once circulation is 
established monitor 
every 1–2 h
A useful resource is the Cholera Outbreak Training and Shigellosis Program that provides free online information about 
the management of patients with cholera, based on WHO standards. ORS=oral rehydration solution. *Patients with 
comorbid disorders including severe malnutrition, signiﬁ cant complications, infants and elderly patients might require 
adjustments from this standard which are detailed in the references. †If losses are in excess of 10 mL/kg per h, use of 
oral therapy might not be possible initially. 
Table 2: Approach to rehydration in a patient with suspected cholera67
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dehydration are in hypovolaemic shock and require 
imme diate intravenous rehydration administered as 
rapidly as possible until circulation is restored. Oral 
rehydration should begin as soon as patients are capable 
of drinking (typically 3–4 h), because more potassium, 
bicarbonate, and glucose are available in oral rehydration 
solution than in standard intravenous ﬂ uids. In patients 
with some dehydration, the initial deﬁ cit should be 
replaced rapidly, with oral rehydration solution when ever 
possible, and patients should be monitored until signs of 
dehydration have resolved. Patients with some dehydration 
but with profound vomiting or continuing stool losses 
can rapidly progress to severe dehydration if only oral 
rehydration solution is provided, and should receive 
concomitant intravenous and oral rehydration. In patients 
without dehydration, management consists of oral ﬂ uids 
to replace continuing losses. WHO oral rehydration 
solution has glucose as the carbohydrate source. Rice-
based oral rehydration solution formu lations, if available, 
have been recorded in randomised trials to reduce the 
duration of diarrhoea and stool losses in severe cholera.93 
Homemade oral rehydration solution can be used in an 
emergency situa tion (table 1). In patients with sympto-
matic hypo glycaemia, 0·25–0·50 g/kg of intravenous 
glucose can be administered and correction of the 
hypoglycaemia monitored until ﬂ uid repletion and the 
ability to take oral rehydration solution has occurred.83
Antibiotics are adjunctive therapy in patients with 
moderate to severe dehydration from cholera.39 As in 
other infections, use of antibiotics in cholera might 
contribute to increasing antimicrobial resistance. How-
ever, eﬀ ective antibiotics shorten the duration of diarrhoea 
and reduce the volume of stool losses by up to 50%; they 
also reduce the duration of shedding of viable organisms 
in stool from several days to 1–2 days.77,100 Antibiotics can 
be administered once the initial ﬂ uid deﬁ cit is corrected 
and vomiting has resolved, ideally within 4 h of initiation 
of therapy. Antibiotic therapy should be based on pre-
vailing local resistance patterns (table 3101–106).
Nutritional interventions include the resumption of 
a high energy diet immediately after the initial ﬂ uid 
deﬁ cit is corrected to prevent malnutrition and 
immediate complications including hypokalaemia 
and hypogly caemia. For infants, breastfeeding should 
be encouraged in concert with oral rehydration solu-
tion. In a randomised trial, zinc supplementation 
reduced the duration of diarrhoea and volume of 
stool in children with cholera.107 Zinc supplementation 
after childhood diarrhoea also reduced the incidence 
of subsequent episodes of diarrhoea for several 
months;108,109 WHO recommends zinc for children 
younger than 5 years of age with diarrhoea (10 mg/day 
for children younger than 6 months and 20 mg/day for 
10 days for children aged 6 months to 5 years67). 
Children with diarrhoea in developing countries also 
beneﬁ t from supplementation with vitamin A.110 
Antimotility agents and antiemetics have no established 
beneﬁ t for treatment of cholera, and might prolong 
infection or have sedating eﬀ ects that interfere with 
eﬀ ective oral rehydration.67,111
In an outbreak, clinicians and public health oﬃ  cials 
often need to manage many patients at the same time. 
Crucial response features include creation of cholera 
treatment centres; training of staﬀ  in case recognition 
and management; and provision of safe water and 
sanitation. Dependent on the local situation, radio 
advertisements, mobile phone messaging, messages on 
billboards, community volunteers, and other methods 
can be impor tant ways to educate the public about 
seeking medical care, oral rehydration use, sanitation, 
and other ways to prevent or minimise transmission. 
Other important components of the public health 
response include disinfectants, proper disposal of waste 
and the bodies of those who die, and coordination of the 
response with community, regional, national, and 
international health authorities. The Cholera Outbreak 
Training and Shigellosis Program is an online resource 
that can assist with management of such features. Some 
countries are reluctant to declare a cholera epidemic 
because of concern about creating panic and the 
implications for tourism and exports; however, rapid 
reporting and a coordinated public health response 
should be encouraged to minimise the extent of the 
outbreak and prevent further spread.
Paediatric dose* Adult dose Comments
Tetracyclines
Tetracycline 12·5 mg/kg per dose, 
four times daily, for 
3 days
500 mg, four times 
daily, for 3 days
Antibiotic resistance to all tetracyclines is 
common.101 Empirical use is most 
appropriate in outbreaks caused by 
documented susceptible isolates. 
Tetracyclines are not recommended for 
pregnant women or children younger 
than 8 years because of risk of irreversible 
discoloration of permanent teeth
Doxycycline 4–6 mg/kg, single dose 300 mg, single dose As for tetracycline
Fluoroquinolones
Ciproﬂ oxacin 15 mg/kg per dose, 
twice a day, for 3 days
500 mg, twice a day, 
for 3 days
In highly susceptible strains, single dose 
ciproﬂ oxacin compares favourably 
against erythromycin102 and doxycycline103 
in randomised trials. However, reduced 
susceptibility to ﬂ uoroquinolones has 
become common in endemic areas, and is 
associated with treatment failure104,105
Macrolides
Erythromycin 12·5 mg/kg per dose, 
four times a day, for 
3 days
250 mg, four times 
a day, for 3 days
There are rare reports of macrolide 
resistance
Azithromycin 20 mg/kg, single dose 1 g, single dose Single dose azithromycin is the preferred 
therapy in children and has been shown 
to be more eﬀ ective than ciproﬂ oxacin in 
randomised trials in regions where 
reduced susceptibility to ﬂ uoroquinolones 
is common106,107
*Paediatric doses, based on weight, should not exceed maximum adult dose.
Table 3: Antibiotics for cholera
For the Cholera Outbreak 
Training and Shigellosis 
Program see http://www.
cotsprogram.com
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Prevention
The response to the cholera pandemics of the 19th century 
led to the development of systems to provide safe water 
and adequate sanitation, but 1 billion people still do not 
have access to safe water and remain at risk of cholera.112 
Continued progress in provision of safe water and 
adequate sanitation is a Millennium Development Goal 
but could take decades to achieve.113 During a cholera 
outbreak, the major response should focus on case 
detection, rehydration-based treatment, and provision of 
safe water, in conjunction with adequate sanitation, 
hand-washing, and safe food preparation.114 These goals 
have been used for decades in areas that remain at risk 
for cholera, without reducing the continuing eﬀ ect of 
this disease, suggesting that consideration of additional 
control strategies, such as vaccination, is warranted.113,115,116
Although safe and eﬀ ective cholera vaccines exist, 
cholera vaccination is not yet part of cholera control 
programmes outside of Vietnam; discussions are in 
progress regarding potential use in Haiti and elsewhere. 
The reasons for this are logistical, ﬁ nancial, and historical. 
Cholera vaccines are given orally, have an excellent safety 
proﬁ le, and target induction of mucosal immunity. Two 
oral killed vaccines, prequaliﬁ ed for use by WHO, are 
licensed and commercially available. Dukoral (WC-rBS, 
Crucell, Sweden) contains several biotypes and serotypes 
of V cholerae O1 supplemented with 1 mg per dose of 
recombinant cholera toxin B subunit. Shanchol (Shantha 
Biotechnics-Sanoﬁ  Pasteur, India) contains several 
biotypes and serotypes of V cholerae O1 and V cholerae 
O139 without supplemental cholera toxin B subunit. 
Shanchol is the bivalent vaccine that is internationally 
available; mORCVAX (VaBiotech, Vietnam) is the locally 
produced Vietnamese version of this vaccine.5
Oral killed cholera vaccines have been administered to 
millions of recipients and are safe and immunogenic. 
The vaccines are administered as two or three doses 
depending on age and vaccine (table 4117–131). Overall, the 
vaccines provide 60–85% protective eﬃ  cacy for 2–3 years, 
although protection among young children is of shorter 
duration.117–127 Dukoral has been safely administered to 
individuals with HIV infection.123
Reanalysis of original studies of oral cholera vaccine in 
Bangladesh in the 1980s disclosed a measurable herd 
eﬀ ect,132 and modelling suggests that vaccination of 
50% of a population could result in a greater than 90% 
reduction in cholera incidence in that population 
overall.133 A cost-eﬀ ectiveness model suggested that oral 
cholera vaccine could be cost eﬀ ective in areas endemic 
for cholera.134
Several live attenuated oral cholera vaccines have also 
been developed, including CVD 103-HgR (PaxVax, USA), 
Peru-15 (Haikou VTI Biological Insitute, China) and 
others.135 These genetically modiﬁ ed vaccine strains have 
in common the inability to express cholera toxin. These 
vaccines have been shown to be safe and immunogenic 
in volunteer studies;136–140 however, CVD 103-HgR failed 
to show protective eﬃ  cacy when assessed in an initial 
ﬁ eld study.141 Peru-15 has been shown to be safe and 
immunogenic in diﬀ erent age groups in Bangladesh,142 
but has not yet been investi gated in ﬁ eld studies. Several 
other cholera vaccines are in various stages of develop-
ment, including subunit vaccines, other live attenuated 
vaccines, and conjugate vaccines.143,144
WHO has endorsed the inclusion of oral vaccine in 
cholera control programmes in endemic areas in con-
junction with other preventive and control strategies.5 
WHO also recommends that oral vaccine be considered 
as part of an integrated control programme in areas at 
risk for outbreaks.5 The use of vaccine in reactive 
situations (ie, after an outbreak has occurred) is less 
certain. A case-control study in Vietnam suggested that 
Doses* Dosing interval* Dosing volume* Boosters* Protective eﬃ  cacy Comments
Dukoral†118–123,128,129
Children aged 
2–5 years
3 14 days 
(7–42 permissible)
3 mL vaccine 
and 75 mL buﬀ er
Every 6 months 60–85% protective 
eﬃ  cacy within 
6 months of 
vaccination, 
decreasing to 
baseline during 
24–36 months
Pre-qualiﬁ ed for use by WHO
Licensed in many countries
Has been safely administered to individuals with 
HIV infection
Provides short-term protection against diarrhoea 
caused by heat labile toxin expressing strains of 
enterotoxigenic E coli
≥6 years 2 14 days 
(7–42 permissible)
3 mL vaccine and 
150 mL buﬀ er
Every 2 years As for children 
2–5 years of age
As for children 2–5 years of age
Shanchol117,124–127,130,131
≥1 year of age 2 14 days (window 
probably same as 
Dukoral)
1·5 mL Every 2 years 60–70% protective 
eﬃ  cacy over 
24–36 months
Pre-qualiﬁ ed for use by WHO
More aﬀ ordable than Dukoral
Does not require buﬀ er to administer vaccine
Undergoing ﬁ eld studies in Kolkata and Orissa, India 
and Dhaka, Bangladesh, and pilot roll-out in Haiti
*Per manufacturer. †Listed ﬁ eld studies have involved both the present preparation of WC-rBS vaccine, supplemented with recombinant cholera toxin B subunit, and a 
previously available preparation of WC-BS containing non-recombinant B subunit.
Table 4: Internationally available killed-cell cholera vaccines for oral administration
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such use could be of beneﬁ t,145 and modelling further 
supports such potential use.55,56,146–148 At present, WHO 
suggests that oral cholera vaccine be considered as part 
of an integrated programme in reactive situations in 
both epidemic and endemic settings in conjunction 
with provision of safe water, adequate sanitation, case 
detection, and rehydration strategies, but that collection 
of additional data to support vaccination in such settings 
is warranted.5 Creation of an international cholera 
vaccine stockpile is being discussed. 
Unanswered questions
Cholera has had an immense eﬀ ect on human history. 
Unfortunately, present control strategies have not proven 
highly eﬀ ective in areas of the world bearing the global 
burden of cholera.113 Many questions remain. Will a new 
serogroup of V cholerae arise, as O139 did? Why are altered 
variants of V cholerae O1 El Tor developing? Will severe 
weather events such as regional ﬂ ooding associated with 
global warming result in increased cholera? What role 
would surveillance, screening, vaccination, or empirical 
treatment have in limiting the spread of cholera into 
immunologically naive popu lations? Would short course 
targeted chemotherapy with highly active antimicrobials 
for close community contacts of patients with cholera 
limit transmission, or only lead to drug resistance? How 
can safe water and improved sanitation be attained in the 
many parts of the world without them? What are the 
obstacles to incorporation of cholera vaccines into 
immunisation programmes in countries where cholera is 
endemic, and how can these be overcome? Who will 
support and pay for the manufacture, distribution, and 
use of cholera vaccines? Will a vaccine stockpile be 
developed? And, if so, who will maintain, monitor, and 
activate its use? Will the development of more eﬀ ective or 
longer acting cholera vaccines than are currently available 
simplify some these decisions?
We do not yet know the answers to these important 
questions, but the way forward will require scientiﬁ c, 
medical, public health, environmental, ﬁ nancial, and 
political cooperation and action. As it has in the past, 
cholera remains largely a disease of impoverishment, 
social unrest and displacement, and continues to be a 
disease of major public health concern.
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